We recently showed that a panel of CD117, BAP1, mTAP, and TdT was able to predict 89% of thymic carcinomas and 78% of type A and B3 thymomas and MNTLS [9], leaving room for improvement in immunohistochemical panels for this differential diagnosis. This evidence concerns the gene MTAP and thymic carcinoma.